Quarterly ResultAug 12, 2026, 05:24 PM
Medicus Pharma Q2 Net Loss $11.68M; Shareholder Deficit $1.72M
AI Summary
Medicus Pharma Ltd. reported a significant widening of its net loss for both the three and six months ended June 30, 2026, reaching $11.68 million and $20.73 million, respectively. The company's shareholders' equity turned into a deficit of $1.72 million, reflecting substantial accumulated losses. Despite the worsening operational performance, Medicus Pharma successfully raised considerable capital through equity offerings and debentures, leading to a notable increase in total assets and cash, but also a corresponding rise in total liabilities.
Key Highlights
- Net loss for the three months ended June 30, 2026, widened to $11.68 million from $6.18 million in the prior year.
- Net loss for the six months ended June 30, 2026, increased to $20.73 million from $11.28 million in the same period last year.
- Shareholders' equity shifted to a deficit of $1.72 million as of June 30, 2026, from a positive $37,311 at December 31, 2025.
- Total assets increased to $27.12 million as of June 30, 2026, from $10.06 million at December 31, 2025.
- Total liabilities significantly rose to $28.84 million from $10.02 million over the same period.
- Net cash provided by financing activities was $32.35 million for the six months ended June 30, 2026, up from $14.92 million.
- Operating expenses for the six months ended June 30, 2026, increased to $20.08 million from $11.14 million.
Price Impact
More from MDCX